Aktuellt
SENASTE
Redeye notes Fluoguide announcing phase IIa top-line data with FG001 in head and neck cancer. Based on previous interim data, we judge that the announced data align with our expectations, showing that FG001 lit up cancer at 4-36 mg doses in all 16 patients with relevant tumour-to-background ratios and no serious adverse events. We nudge up our valuation.
LÄS MER
